The activation of SIRT1 by resveratrol reduces breast cancer metastasis to lung through inhibiting neutrophil extracellular traps

• Published in: Journal of drug targeting 2023-12, Vol.31 (9), p.962-975
• Main Authors: Yu, Wenyan, Wang, Zhuning, Dai, Ping, Sun, Jing, Li, Jian, Han, Wei, Li, Kaichun
• Format: Article
• Language: English
• Subjects: Animals; DNA; Extracellular Traps - metabolism; Lung; Lung Neoplasms - pathology; Mice; Resveratrol - pharmacology; Sirtuin 1 - metabolism
• ISSN: 1061-186X; 1029-2330
• DOI: 10.1080/1061186X.2023.2265585

Neutrophil extracellular traps (NETs) play a crucial role in breast cancer metastasis. However, the therapeutic target of NETs in breast cancer metastasis is still unknown. Using a natural metabolite library and single-cell sequencing data analysis, we identified resveratrol (RES), a polyphenolic natural phytoalexin, and agonist of silent information regulator-1 (SIRT1) that suppressed NETs formation after cathepsin C (CTSC) treatment. , RES significantly hindered breast cancer metastasis in a murine orthotopic 4T1 breast cancer model. Serum levels of myeloperoxidase-DNA and neutrophil elastase-DNA in mouse breast cancer model were significantly lower after RES treatment. Correspondingly, the tumour infiltrated CD8 T cells in the lungs increased after the treatment. Mechanistically, RES targets SIRT1 in neutrophils and significantly inhibits the citrullination of histones H3, which is essential for chromatin decondensation and NETs formation. Furthermore, we identified that the NETs were suppressed by RES in bone marrow neutrophils after CTSC treatment, while specific deficiency of SIRT1 in neutrophils promoted NETs formation and breast cancer to lung metastasis. Thus, our results revealed that RES could be potentially identified as a viable therapeutic drug to prevent neutrophil cell death and breast cancer metastasis.